Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joanne M Munck

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
The Journal of Cell Biology|December 2, 2009
A dual function for Pex3p in peroxisome formation and inheritanceJoanne M Munck, Alison M Motley, James M Nuttall, et al.
Cancer Chemotherapy and Pharmacology|June 2, 2011
Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombinationMichele Tavecchio, Joanne M Munck, Celine Cano, et al.
Biology Open|August 17, 2013
Intra-ER sorting of the peroxisomal membrane protein Pex3 relies on its luminal domainMohammad H Fakieh, Peter J M Drake, Joanne Lacey, et al.
Communications Biology|April 24, 2025
The identification of functional regions of MEK1 using CRISPR tiling screensZhiqiang Zhang, Barbara Abreu, Jessica L Brothwood, et al.
Molecular Cancer Therapeutics|November 22, 2019
Dual-Mechanism ERK1/2 Inhibitors Exploit a Distinct Binding Mode to Block Phosphorylation and Nuclear Accumulation of ERK1/2Andrew M Kidger, Joanne M Munck, Harpreet K Saini, et al.
Molecular Cancer Therapeutics|October 29, 2014
Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma modelsTomoko Smyth, Kim H T Paraiso, Keisha Hearn, et al.
Molecular Cancer Therapeutics|April 27, 2018
ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor GrowthGeorge A Ward, Edward J Lewis, Jong Sook Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2014
DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survivalLiam Cornell, Joanne M Munck, Clara Alsinet, et al.
Molecular Cancer Therapeutics|August 14, 2021
Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal CancerNyree Crawford, Katie J Stott, Tamas Sessler, et al.
Molecular Cancer Therapeutics|May 12, 2012
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3KJoanne M Munck, Michael A Batey, Yan Zhao, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
The Journal of Cell Biology|December 2, 2009
A dual function for Pex3p in peroxisome formation and inheritanceJoanne M Munck, Alison M Motley, James M Nuttall, et al.
Cancer Chemotherapy and Pharmacology|June 2, 2011
Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombinationMichele Tavecchio, Joanne M Munck, Celine Cano, et al.
Biology Open|August 17, 2013
Intra-ER sorting of the peroxisomal membrane protein Pex3 relies on its luminal domainMohammad H Fakieh, Peter J M Drake, Joanne Lacey, et al.
Communications Biology|April 24, 2025
The identification of functional regions of MEK1 using CRISPR tiling screensZhiqiang Zhang, Barbara Abreu, Jessica L Brothwood, et al.
Molecular Cancer Therapeutics|November 22, 2019
Dual-Mechanism ERK1/2 Inhibitors Exploit a Distinct Binding Mode to Block Phosphorylation and Nuclear Accumulation of ERK1/2Andrew M Kidger, Joanne M Munck, Harpreet K Saini, et al.
Molecular Cancer Therapeutics|October 29, 2014
Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma modelsTomoko Smyth, Kim H T Paraiso, Keisha Hearn, et al.
Molecular Cancer Therapeutics|April 27, 2018
ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor GrowthGeorge A Ward, Edward J Lewis, Jong Sook Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2014
DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survivalLiam Cornell, Joanne M Munck, Clara Alsinet, et al.
Molecular Cancer Therapeutics|August 14, 2021
Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal CancerNyree Crawford, Katie J Stott, Tamas Sessler, et al.
Molecular Cancer Therapeutics|May 12, 2012
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3KJoanne M Munck, Michael A Batey, Yan Zhao, et al.
Pageof 2